Two recent studies suggested that targeting MDSCs via the antagonism of GM-CSF and fatty acid transport protein 2 (FATP2) by using lipofermata decreased ROS and PGE2-levels and their immunosuppressive functions in tumor-bearing mice (50, 51). This evidence concerns the gene SLC27A2 and neoplasm.